

**Douglas E Ney, MD, FAAN**  
***Updated 6/5/2025***

**Current Position**

Professor of Neurology and Neurosurgery  
Vice Chair of Education, Department of Neurology  
Director, Neurology Residency Program  
University of Colorado School of Medicine

**Address**

University of Colorado School of Medicine  
Research 2 Building, MS B-182  
12700 E 19<sup>th</sup> Ave. Room 5011  
Aurora, CO 80045  
Phone: 303-724-2184  
Fax: 303-724-2213  
[Douglas.Ney@cuanschutz.edu](mailto:Douglas.Ney@cuanschutz.edu)

**Education and Training**

|           |   |
|-----------|---|
| 1999      | BA with Honors, Magna cum laude, Music, Allegheny College, Meadville, PA        |
| 2003      | MD, University of Rochester School of Medicine and Dentistry, Rochester, NY     |
| 2003-2004 | Intern, Internal Medicine, University of Vermont Medical Center, Burlington, VT |
| 2004-2006 | Resident, Neurology, University of Vermont Medical Center, Burlington, VT       |
| 2006-2007 | Chief Resident, Neurology, University of Vermont Medical Center, Burlington, VT |
| 2007-2009 | Fellow, Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY    |

**Academic Appointments**

|              |   |
|--------------|---|
| 2009-2015    | Assistant Professor, Departments of Neurology and Neurosurgery<br>University of Colorado School of Medicine, Aurora, CO |
| 2015-2022    | Associate Professor, Departments of Neurology and Neurosurgery<br>University of Colorado School of Medicine, Aurora, CO |
| 2015-2016    | Associate Residency Program Director, Department of Neurology<br>University of Colorado School of Medicine, Aurora, CO  |
| 2016-present | Program Director, Neurology Residency Program<br>University of Colorado School of Medicine, Aurora, CO                  |
| 2022-present | Professor, Departments of Neurology and Neurosurgery<br>University of Colorado School of Medicine, Aurora, CO           |
| 2022-present | Vice Chair of Education, Department of Neurology<br>University of Colorado School of Medicine                           |

**Other Professional Positions**

2013-2014 Novocure Glioblastoma (GBM) Advisory Board Member, Novocure, Inc.  
2014 Prime Oncology Invited Speaker  
2016-2021 DNATRIX Data Safety Monitoring Committee  
2025- Center for Personalized Education for Professionals Practice Monitor

**Honors and Awards**

1997 Lambda Sigma Honor Society, Allegheny College, Vice-President  
1998 Summer Research Fellowship, Case Western Reserve University School of Medicine  
1998 Outstanding summer research, Case Western Reserve University School of Medicine  
1999 Phi Beta Kappa, Allegheny College  
2002 Strong Children's Summer Research Fellowship, University of Rochester School of Medicine  
2007 J. Kiffin Penry Epilepsy Mini-Fellowship  
2007-2009 Clinical Research Methodology Course, Memorial Sloan-Kettering Cancer Center  
2010 NINDS Clinical Trial Methods Course in Neurology, Vail, Colorado  
2012 ANA Translational and Clinical Research Course in the Neurosciences, SF, CA  
2016 CUSOM Academy of Medical Educators Teaching Certificate Program  
2018 Academy of Medical Educators, University of Colorado School of Medicine  
2019 AAN Live Well, Lead Well: Well-Being Champion Leadership Program  
2019 AAN Educators' Leadership Program  
2019 5280 Magazine Top Doctor, Neurology  
2022 University of Colorado School of Medicine Neurology Medical Student Teaching Award  
2022-2023 Harvard Macy Institute Program for Educators in Health Professions  
2023 Stanford Physician Leadership Certificate Program  
2023 Fellow of the American Academy of Neurology (FAAN)

**Memberships in Professional Organizations**

2005-present American Academy of Neurology  
2007-present American Society of Clinical Oncology  
2007-present Society for Neuro-Oncology  
2013-present American Neurological Association  
2016-present Association for University Professors of Neurology

**Major Committee and Service Responsibilities**

**Departmental:**

2010-2012 Residency Program Evaluation and Promotions Committee  
2011-2015 Neurology Resident Faculty Mentor  
2011-present Resident Education Neuro-Oncology Block Director  
2012-2018 Incentive Committee

|              |  |
|--------------|--|
| 2012-2016    | Faculty Senator for Department of Neurology        |
| 2013-present | Neurology Performance Improvement Committee        |
| 2015-present | Neurologic Care Clerkship Grading Committee        |
| 2015-present | Resident Selection Committee                       |
| 2015-present | Neurology Residency Program Evaluation Committee   |
| 2015-present | Neurology Residency Clinical Competency Committee  |
| 2015-present | Neurology Residency Education Curriculum Committee |
| 2016-present | Neurology Quality Case Review Committee            |
| 2016         | Faculty Judge, Neurology Resident Research Retreat |
| 2016-present | Departmental Faculty Promotion Committee           |
| 2016-present | eRVU Committee                                     |
| 2017-present | Neurology Clinical Affairs Committee               |

**Hospital:**

|              |  |
|--------------|--|
| 2009- 2014   | Protocol Review and Monitoring Committee, University of Colorado Cancer Center |
| 2017-present | Laboratory Orders Optimization Committee                                       |
| 2018-present | CME Course Director Neuro-Oncology Multidisciplinary Clinic                    |

**University:**

|              |  |
|--------------|--|
| 2016-2025    | Graduate Medical Education Committee                       |
| 2019-2025    | Graduate Medical Education: Education Subcommittee         |
| 2020-present | CUSOM Admissions Interview Subcommittee                    |
| 2020-present | UCO UM1 ETCTN Brain Disease-Site Lead                      |
| 2021-2022    | Co-Chair Academy of Medical Educators Membership Committee |
| 2024-        | SOM CQI Committee  |

**National:**

|           |   |
|-----------|---|
| 2015-     | ECD Care Center: University of Colorado Lead Physician                |
| 2016-2017 | American Academy of Neurology: Neuro-Oncology Measurement Work Group  |
| 2018-2025 | UCNS Neuro-Oncology Examination Committee                             |
| 2019      | AAN Quality Measure Subcommittee                                      |
| 2019-2021 | AAN Quality Measures Subcommittee PROM Workgroup                      |
| 2019-2021 | ASCO Expert Panel Member: Systemic Anti-Neoplastic Therapy for Glioma |
| 2019-2022 | ASCO International Education Steering Group (IESG)                    |
| 2020-2021 | AAN Quality Measure Subcommittee Evidence Review Group Co-Facilitator |
| 2021-2023 | ANA Education Innovation Committee                                    |
| 2023-2024 | ASCO-SEP Item Writing Task Force (CNS)                                |
| 2024-     | ASCO-SEP Item Writing Task Force Co-Chair (CNS)                       |
| 2023-2024 | ANA Neuro-Oncology Special Interest Group Vice-Chair/Chair (2024)     |
| 2023-     | NCCN Histiocytic Neoplasms Panel Member                               |
| 2023-     | UCNS Certification Council  |
| 2023-     | NCCN Central Nervous System Tumors Panel Member                       |

2024- ASCO Measures Steering Group

### **Licensure and Board Certification**

|              |   |
|--------------|---|
| 2004         | National Board of Medical Examiners   |
| 2007-2009    | State of New York Medical Licensure – inactive                              |
| 2008         | Diplomate, American Board of Psychiatry and Neurology                       |
| 2009-present | State of Colorado Medical Licensure   |
| 2013         | United Council of Neurologic Subspecialties Certification in Neuro-Oncology |
| 2018         | Recertification in Neurology, American Board of Psychiatry and Neurology    |

### **Review and Referee Work**

**Ad hoc reviewer:** All Life; Aging and Cancer; Antibodies; Anti-Cancer Agents in Medicinal Chemistry; Annals of Medicine; Annals of Neurology; Arquivos de Neuro-Psiquiatria; BMC Cancer; BMJ Case Reports; BMC Health Services Research; BMC Neurology; BMC Ophthalmology; Cancers; Cancer Control; Cancer Growth and Metastasis; Cancer Medicine; Clinics and Practice; Current Oncology; Diagnostics; Frontiers in Oncology; Healthcare; International Journal of Radiation Oncology, Biology, Physics; Neurology; Journal of Clinical and Medical Case Reports; Journal of Clinical Medicine; Journal of Chemotherapy; Journal of Neurology and Neurosurgery; ; The Journal of Neuropsychiatry and Clinical Neurosciences; Journal of Neurology and Stroke; Journal of Neuro-Oncology; Journal of Oncology; Journal of Palliative Medicine; Journal of Thoracic Oncology; Medicine; Neurology; Neurology: Clinical Practice; Neuro-Oncology Practice; The Neurohospitalist; Neurology Research International; Neuro-Oncology Clinical Practice; Neuro Research; Neurosurgical Reviews; OncoTargets and Therapy; Oxford Medical Case Reports; Plos One

**Editorial boards:** Central Nervous System Tumours/Clinics in Oncology; Journal of Neurology and Neurosurgery; SM Journal of Neurological Disorders and Stroke;

**Abstract reviewer:** ANA Annual Meeting (2015-2024); ANA Annual Meeting CME reviewer (2019, 2023-2024); WGEA Regional Meeting (2018); AAMC Call for Medication Education (2018); Society of Neuro-Oncology Annual Meeting (2020-2024)

**Grant reviewer:** Erdheim Chester Disease Global Alliance (2015, 2021, 2025); University of Colorado Cancer Center Developmental Therapeutics Early Development (2017)

### **Invited Extramural Lectures and Presentations**

|      |   |
|------|---|
| 2007 | University of Vermont Neuroscience Grand Rounds; Burlington, VT, Paraneoplastic Disorders of the CNS. (5/30/2007)   |
| 2010 | University of Pittsburgh Medical Center Brain Tumor Conference; Pittsburgh, PA. Angiogenesis in malignant glioma: Implications for treatment and further challenges. (10/29/2010) |

- 2015 Lutheran Medical Center Cancer Education Series; Wheat Ridge, CO. Chemo Brain. (5/12/15)
- 2016 Blood-Brain Barrier Mid-Annual Meeting; Portland, OR. Treatment of Primary CNS Lymphoma at the University of Colorado. (10/07/16).
- 2019 American Society of Clinical Oncology Meeting; Chicago, IL. Invited Discussant. Enhancing Education Through Technology. (6/03/19)
- 2019 ASCO Oncology Training Program Directors' Retreat; Alexandria, VA. eRVU Credit for Teaching Faculty. (10/17/19)
- 2021 Colorado Neurological Society Lecture. WHO CNS 2021: Implications for adult patients with glioma. (5/27/21)
- 2022 Stony Brook University Department of Neurology Grand Rounds. Primary CNS Lymphoma: Where we've come from and where we're going. (1/14/22)

**Invited Intramural Lectures and Presentations**

- 2009 University of Colorado Neurology Grand Rounds. Angiogenesis in malignant glioma. (2/4/2009)
- 2011 University of Colorado Neurology Grand Rounds. Recurrent Glioblastoma: Challenges and Opportunities. (3/3/2011)
- 2012 University of Colorado Neuropsychiatry Lecture. Primary Brain Tumors in Adults. (6/18/12)
- 2012 University of Colorado Neurosciences Grand Rounds. Primary CNS Lymphoma: Are we better off now than four years ago? (9/19/2012)
- 2013 University of Colorado Neurosciences Grand Rounds. Field of dreams: a novel treatment for recurrent glioblastoma. (5/22/13)
- 2013 University of Colorado Neurology Grand Rounds (co-presenter). Detecting and treating depression in progressing neurological disorders. (8/14/13)
- 2014 University of Colorado Neurosciences Grand Rounds (co-presenter). Immunological therapies for glioblastoma (5/16/2014)
- 2014 University of Colorado Neurosciences Grand Rounds. Chemobrain: is systemic chemotherapy really neurotoxic? (9/10/14)
- 2016 University of Colorado Neurosciences Grand Rounds. Controversies in the management of lymphomatous meningitis. (2/10/16)
- 2016 University of Colorado Rehabilitation Study Group. Brain Tumors in Adults: Rehabilitation Considerations. (9/27/16)
- 2016 University of Colorado Brain Tumor Education Day. Understanding Treatment Related Complications. (10/15/16)
- 2017 University of Colorado Radiation Oncology Lecture Series. Immunotherapy Approaches to Malignant Glioma. (3/03/17)
- 2018 University of Colorado Neurosciences Summit. Neurologic and Medical Management of the Brain Tumor Patient. (9/14/18)
- 2018 University of Colorado Anschutz Cancer Center Infusion Center Meeting. What you need to know about brain tumors. (9/20/18)
- 2019 University of Colorado BMT Program Grand Rounds. Updates in Primary CNS Lymphoma. (1/09/19)
- 2019 University of Colorado Neurohospitalist Didactics. Neurologic and medical management of the brain tumor patient. (3/14/19)

- 2019 University of Colorado Annual Meningioma Patient Education Day. Medical Management of Meningioma. (11/9/19)
- 2019 University of Colorado Annual Meningioma Patient Education Day. Neurologic complications secondary to meningiomas. (11/9/19)
- 2023 University of Colorado Neurosciences Grand Rounds. Updates in Erdheim-Chester Disease (8/02/23)
- 2024 University of Colorado Neurosciences Grand Rounds. Gliomas in particular persons and places. (2/21/24)
- 2025 University of Colorado Genetics Counselors Retreat. Neurocutaneous Syndromes. (4/25/25)

## **Teaching Record**

### **Presentations to House Officers**

- 2008 Memorial Sloan-Kettering Nursing Lecture; Principles of Paraneoplastic Disorders. (1/14/2008)
- 2008 Memorial Sloan-Kettering Fellows Lecture; Paraneoplastic Disorders. (3/10/2008)
- 2008 Memorial Sloan-Kettering Fellows Lecture; Intrathecal chemotherapy for leptomeningeal disease. (6/16/2008)
- 2009 Memorial Sloan-Kettering Fellows Lecture; Angiogenesis in malignant glioma. (1/31/2009)
- 2010 University of Colorado Medical Oncology Fellows Lecture, Neuro-Oncology Review. (11/29/2010).
- 2011 University of Colorado Medical Oncology Fellows Lecture, Neuro-Oncology for Medical Oncologists. (11/4/2011)
- 2012 University of Colorado Neurology Resident Lectures, Paraneoplastic Syndromes. (4/11/12)
- 2012 University of Colorado Neurology Resident Lectures, Neurologic complications of cancer. (4/11/12)
- 2012 University of Colorado Neurology Resident Lectures, Emergencies in Neuro-Oncology. (7/11/12)
- 2012 University of Colorado Oncology Fellow's Lecture, Neuro-Oncology: old and new. (11/12/12)
- 2013 University of Colorado Neurology Resident Lectures, Paraneoplastic syndromes. (3/27/13).
- 2013 University of Colorado Neurology Resident Lectures, Neurologic complications of cancer. (3/27/13).
- 2013 University of Colorado Neurology Resident Lectures, Neuro-Oncology Case Review. (4/10/13).
- 2013 University of Colorado Neurology Resident Emergencies Lecture Series, Emergencies in Neuro-Oncology. (7/31/13).
- 2014 University of Colorado Medical Oncology Fellow's Lecture Series, Primary brain tumors in a nutshell". (6/6/14)
- 2014 University of Colorado Neurology Resident Lectures, Emergencies in Neuro-Oncology. (7/23/14)

- 2015 University of Colorado Neurology Resident Lectures, Paraneoplastic disorders. (3/25/15)
- 2015 University of Colorado Neurology Resident Lectures, Neurological complications of cancer. (4/01/15)
- 2015 University of Colorado Neurology Resident Lectures, Emergencies in Neuro-Oncology. (7/29/15)
- 2015 University of Colorado Radiation Oncology Resident Education Lectures, Tumor Treating Fields: A New Option for Glioblastoma. (1/21/16)
- 2016 University of Colorado Neurology Resident Lectures, Neurologic complications of Cancer. (4/13/12)
- 2016 University of Colorado Neurology Resident Lectures, Neuro-Oncology Emergencies. (7/27/16)
- 2017 University of Colorado Neurology Residency Lectures, NeuroPhakomatoses. (3/29/17)
- 2017 University of Colorado Neurology Residency Lectures, Neurologic Complications of Cancer. (4/05/17)
- 2017 University of Colorado Neurology Residency Lectures, Case Reviews in Neuro-Oncology. (4/05/17)
- 2017 University of Colorado Oncology Fellow Lectures, Neuro-Oncology: Principles and Practice (9/15/17)
- 2017 University of Colorado Radiation Oncology Resident Lectures: Chemotherapy for recurrent malignant glioma (11/20/17)
- 2017 University of Colorado Neurology Resident Lectures. Case Reviews in Neuro-Oncology 1 and 2. (2/21/18)
- 2018 University of Colorado Neurology Resident Lectures. Emergencies in Neuro-Oncology. (8/8/18)
- 2018 University of Colorado Radiation Oncology Resident Lectures. Leptomeningeal disease in solid tumors. (9/28/18)
- 2019 University of Colorado Medical Oncology Fellow Lectures. Updates in Neuro-Oncology. (2/22/19)
- 2019 University of Colorado Neurology Resident Lectures. Gliomas. (3/20/19)
- 2019 University of Colorado Neurology Resident Lectures. Neuro-Oncology Pearls. (3/20/19)
- 2019 University of Colorado Neurology Resident Lectures. Inpatient Neuro-Oncology Management. (7/24/19)
- 2019 University of Colorado Neurology Resident Lectures. Personal Branding. (10/02/19)
- 2019 University of Colorado Heme/Onc Fellow Lectures. Leptomeningeal disease in patients with solid tumors. (10/04/19)
- 2020 University of Colorado Neurology Resident Lectures. Glioma management. (3/11/20)
- 2020 University of Colorado Neurology Resident Lectures. Inpatient Neuro-Oncology Management. (7/15/20)
- 2020 University of Colorado Oncology Fellows Lecture. Neuro-Oncology Updates. (9/25/20)

- 2020 University of Colorado Oncology Fellows Lecture. Neuro-Oncology Updates 2. (10/23/20)
- 2021 University of Colorado Neurology Resident Lectures. Personal Branding in Academic Medicine. (3/10/21)
- 2021 University of Colorado Neurology Resident Lectures. Meningiomas and inheritable brain tumor syndromes. (4/21/21)
- 2021 University of Colorado Neurology Resident Lectures. Inpatient Neuro-Oncology Management. (7/21/21)
- 2022 University of Colorado Neurology Resident Lectures. Gliomas. (5/18/22)
- 2022 University of Colorado Neurology Resident Lectures. Acute Inpatient Neuro-Oncology Management. (8/24/22)
- 2023 University of Colorado Neurology Resident Lectures. Gliomas – Part 1 (3/29/23)
- 2023 University of Colorado Neurology Resident Lectures. Gliomas – Part 2 (3/29/23)
- 2023 University of Colorado Neurology Resident Lectures. Neuro-Oncology Cases (3/29/23)
- 2023 University of Colorado Neurology Resident Lectures. Curiosity in medicine (7/26/23)
- 2023 University of Colorado Neurology Resident Lectures. Inpatient Neuro-Oncology management (8/23/23)
- 2024 University of Colorado Neurology Residency Lectures. Wellness: End-of-life discussions (2/21/24)
- 2024 University of Colorado Neurology Residency Lectures. Primary Brain Tumors. (3 hours) (5/15/24)
- 2024 University of Colorado Hem/Onc Fellow Lectures. Gliomas. (6/21/24)
- 2025 University of Colorado Hem/Onc Fellow Lectures. Primary CNS Lymphoma. (3/14/25)
- 2024 University of Colorado Neurology Residency Lectures. End-of-life discussions. (3/26/24)

**Medical Students:**

- 2011 Foundations of Doctoring Curriculum: Neurological Examination (2 sessions)
- 2012 Facilitator for SOM Orientation Exercise in Narrative Writing (8/12/12)
- 2012-2013 Phase I PBL facilitator for 1<sup>st</sup> year medical students (21 sessions)
- 2012 Facilitator for Clinical Interlude Debriefing for 1<sup>st</sup> year medical students (12/14/12)
- 2013 Facilitator for Small Group SOAP Note Session for 1<sup>st</sup> year medical students (1/24/13)
- 2013 Phase II PBL facilitator for 2<sup>nd</sup> year medical students (10 sessions)
- 2013 Foundations of Doctoring Curriculum: Neurological Examination (2 sessions; 9/27/13)
- 2014 Facilitator for Foundations of Doctoring Curriculum: SOAP notes Phase I
- 2014 Facilitator for Interprofessional Education and Development – Spring Session (8 sessions)
- 2014-2015 Facilitator for Phase III Hidden Curriculum (4 sessions)



|           |   |
|-----------|---|
| 2014      | Facilitator for Interprofessional Education and Development Orientation Session         |
| 2014      | Facilitator for Interprofessional Education and Development – Fall Session (8 sessions) |
| 2014-2015 | Phase I PBL facilitator for 1 <sup>st</sup> year medical students (21 sessions)         |
| 2015      | Facilitator for ICC 8004; Shared Decision Making/Informed Consent (3/11/15)             |
| 2015      | Facilitator for ICC 7001; Professionalism (4/24/15)                                     |
| 2014-2016 | Foundations of Doctoring Preceptor  |
| 2015-2016 | Phase II PBL facilitator for 2 <sup>nd</sup> year medical students (11 sessions)        |
| 2015      | Facilitator for ICC2: Reflective Writing session (12/18/15)                             |
| 2016      | Facilitator for Phase IV Hidden Curriculum (2 sessions)                                 |
| 2016-2017 | Facilitator for Phase III Hidden Curriculum (4 sessions)                                |
| 2016      | Facilitator for Phase III Professionalism Session (4/22/16)                             |
| 2016-2017 | Phase I PBL facilitator for 1 <sup>st</sup> year medical students (21 sessions)         |
| 2016      | Facilitator for Neurologic Care Clerkship PBL   |
| 2016      | Facilitator for Phase I Professionalism Session (9/29/16)                               |
| 2017      | Facilitator for ICC 8004: Shared Decision Making (3/06/17)                              |
| 2017-2018 | Phase II PBL facilitator for 2 <sup>nd</sup> year medical students (11 sessions)        |
| 2018      | Facilitator for Phase IV Hidden Curriculum (2 sessions)                                 |
| 2018-2019 | Phase I PBL facilitator for 1 <sup>st</sup> year medical students (21 sessions)         |
| 2019      | Facilitator for ICC 7003: Handoffs (4/24/19)  |
| 2019      | Facilitator for IDPT 8005: Residents as Teachers (5/16/19)                              |
| 2019-2020 | Phase II PBL facilitator for 2 <sup>nd</sup> year medical students (12 sessions)        |
| 2020-2021 | Facilitator for Phase III Hidden Curriculum (5 sessions)                                |
| 2020      | Facilitator for Neurology Clerkship Small Group Sessions (3 sessions)                   |
| 2020-2022 | Phase 1 Foundations of Doctoring Preceptor (Drew Gottman)                               |
| 2021-     | MSTP Foundations of Doctoring Preceptor (Chris Alderman)                                |
| 2021      | Facilitator for IPDT 7003: Error Disclosure (5/18/21)                                   |
| 2021      | Facilitator for MS1 Professionalism II session (11/17/21)                               |
| 2021      | Facilitator for Hidden Curriculum (4 sessions)  |
| 2023      | Facilitator for MS1 Professionalism session (7/26/23)                                   |
| 2023-2024 | Foundations of Doctoring Preceptor (Noon Awad)  |
| 2024-     | Foundations of Doctoring Preceptor (Katherine Kesselman)                                |

**Residents:**

|               |   |
|---------------|---|
| 2012- present | Neuro-Oncology Education Block Director                         |
| 2012- present | Neurology Resident Education Series Lecturer                    |
| 2014-2017     | Neurology Journal Club Facilitator                              |
| 2015-2016     | Clinical Coaching Program for Medicine PGY-1 Resident           |
| 2016-present  | Facilitator for Neurology Resident Lunch Reports                |
| 2016-present  | Supervising Attending for Neurology Resident Continuity Clinics |

**Fellows:**

|              |  |
|--------------|--|
| 2010-present | Lecturer, Medical Oncology Fellows Core Seminar Series: Neuro-Oncology |
|--------------|--|

2014-present     Neuro-Oncology Fellow Mentor

**Ward/Clinic Attending**

2009-present     Attending. Neuro-Oncology outpatient clinics with supervision and teaching of undergraduate students, medical students, residents and fellows: ~25 hours month.

2011-2017        Attending on Neurology Inpatient Ward and Consult service (2-3 weeks/year)

2011-2017        Night call UCH Neurology Attending. Home call supervision of housestaff

**Active Clinical Trials**

1. Principal Investigator. COMIRB 23-2578. NCI 10559: A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion. UM1 ECTCN LAO-NC010.
2. Principal Investigator. COMIRB 23-1257. A Phase II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients with MGMT Unmethylated Glioblastoma. Cantex Pharmaceuticals.
3. Principal Investigator. COMIRB 23-009. NCI 10505: A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma. UM1 ECTCN LAO-NC010.
4. Principal Investigator. COMIRB 21-4799. NRG-BN010: A safety run-in and phase II study evaluating the efficacy, safety, and impact on the tumor microenvironment of the combination of tocilizumab, atezolizumab, and fractionated stereotactic radiotherapy in recurrent glioblastoma. NRG-BN010.
5. Sub-Investigator. COMIRB 21-4778. An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL). Ono Pharma ONO-4059-09
6. Sub-Investigator. COMIRB 21-3021. Alliance A071702: Phase 2 Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent GBM. Alliance/SWOG
7. Principal Investigator. COMIRB 21-2740. A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma. NCI Protocol #10218/ECTCN LAO UM1.
8. Principal Investigator. COMIRB 20-326. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1. Denovo Biopharma.
9. Sub-Investigator. COMIRB 19-2707. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation. Agios.
10. Sub-Investigator. COMIRB 19-0744. GCAR-7213 GBM AGILE. Global Adaptation Trial.
11. Principal Investigator. COMIRB 19-0423. A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for

Recurrent High-Grade Radiation-Relapsed Meningioma. NCI # 10186/ECTCN LAO-NC010.

12. Principal Investigator. COMIRB 18-1336. A Phase 3, Randomized Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy. Orbus Therapeutics.
13. Principal Investigator. COMIRB 17-206. A randomized phase 2 trial of cediranib and olaparib compared to bevacizumab in patients with recurrent glioblastoma who have not received prior VEGF therapy. LOA-MA036. Closed to accrual.
14. Principal Investigator. COMIRB 17-1486. A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma. BeiGene. Closed to accrual.
15. Principal Investigator. COMIRB 16-105. Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders. Investigator Initiated. Primary Site: OHSU. Funding: Genentech.
16. Principal Investigator. COMIRB 16-0953. A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients with Recurrent Glioblastoma. Kadmon. Closed to accrual.
17. Sub-Investigator. COMIRB 16-0200. RTOG 3508. A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intelligence I). Closed to accrual.
18. Sub-Investigator. COMIRB 15-1752. A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma. Tocagen Inc. Closed to accrual.
19. Sub-Investigator. COMIRB 15-1747. A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations. Alliance. Closed to accrual.
20. Sub-Investigator. COMIRB 15-1664. ICT-107-301: Study of Immunotherapy in Newly Diagnosed Glioblastoma: A Phase III Randomized Double-Blind, Controlled Study of ICT-107 with Maintenance Temozolomide in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemotherapy. Immunocellular Therapeutics. Closed to accrual.
21. Sub-Investigator. COMIRB 15-0398. A07112: A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation. Alliance. Closed to accrual.
22. Sub-Investigator. COMIRB 15-0164. M14-483/EORTC 1410-BTG: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group. Abbvie. Closed to accrual.
23. Sub-Investigator. COMIRB 14-0012. Clinical Study Protocol AG120-C-002: A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic,

Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation. Agios. Closed to accrual.

24. Principal Investigator. COMIRB 14-2216. Pilot Study of NovoTTF-100A for Recurrent Atypical and Anaplastic Meningioma. Investigator Initiated. Primary Site: MSKCC. Funding: Novocure. Closed to accrual.
25. Sub-Investigator. COMIRB 14-2171. A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancer. Incyte Corporation. Closed to accrual.
26. Co-Investigator. COMIRB 14-1941. RTOG 1071/NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone Versus radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma. RTOG. Closed to accrual.
27. Principal Investigator. COMIRB 13-0289. A Prospective, Multi-center Trial of NovoTTF-100A Together with Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM. Novocure, Inc. Closed to accrual.
28. Co-Investigator. COMIRB 13-3160. RTOG 1205: Randomized Phase II trial of concurrent bevacizumab and re-irradiation versus bevacizumab alone as treatment for recurrent glioblastoma. Radiation Therapy Oncology Group. Closed to accrual.
29. Sub-Investigator. COMIRB 11-1777. A Phase II Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme. Northwest Biotherapeutics. Closed to accrual.
30. Principal Investigator. COMIRB 10-0264. A Pilot Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) and Bevacizumab for Patients with Newly Diagnosed Glioblastoma Multiforme (GBM). Investigator Initiated. Closed to accrual.
31. Principal Investigator. COMIRB 05-0562. A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM). Investigator Initiated. Closed to accrual.

### **Quality Improvement Activities**

1. Principal Investigator. Development of a Multidisciplinary Rehabilitation Neuro-Oncology Clinic. University of Colorado Patient Safety and Clinical Effectiveness Grant. Award total: \$25,000; August 2014.
2. Project Lead. Detection of Depression in patients with primary brain tumors. April 2013-ongoing.
3. Member/Neuro-Oncology Representative. Neurology Department Performance Improvement/Quality Assurance Committee. April 2013-present.

### **Peer Reviewed Journal Publications:**

<https://www.ncbi.nlm.nih.gov/myncbi/douglas.ney.1/bibliography/public/>

1. **Ney DE**, Lassman AB. Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions. *Curr Oncol Rep*. Jan 2009;11(1):62-67. doi:10.1007/s11912-009-0010-x

2. **Ney DE**, Abrey LE. Maintenance therapy for central nervous system lymphoma with rituximab. *Leuk lymphoma*. Sep 2009;50(9):1548-1551. doi:10.1080/10428190903128645
3. Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, **Ney DE**, Lassman AB. Bevacizumab for recurrent ependymoma. *Neurology*. Nov 2009;73(20):1677-1680. doi:10.1212/WNL.0b013e3181c1df34
4. **Ney DE**, Huse JT, Dunkel IJ, Steinherz PG, Haque S, Khakoo Y. Intraventricular meningioma after cranial irradiation for childhood leukemia. *J Child Neurol*. Oct 2010;25(10):1292-1295. doi:10.1177/0883073810362267
5. **Ney DE**, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center experience. *Cancer*. Oct 2010;116(19):4605-4612. doi:10.1002/cncr.25363
6. Reddy K, Damek D, Gaspar LE, **Ney D**, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. *Int J Radiat Oncol Biol Phys*. Nov 2012;84(3):655-660. doi:10.1016/j.ijrobp.2012.01.035
7. Khalil A, Serracino H, Damek DM, **Ney D**, Lillehei KO, Kleinschmidt-DeMasters BK. Genetic characterization of gliomas arising in patients with multiple sclerosis. *J Neurooncol*. Sep 2012;109(2):261-272. doi:10.1007/s11060-012-0888-2
8. Reddy K, Gaspar LE, Kavanagh BD, Waziri A, Damek DM, **Ney D**, Lillehei KO, Chen C. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. *J Neurooncol*. Aug 2013;114(1):111-116. doi:10.1007/s11060-013-1159-6
9. **Ney DE**, Messersmith W, Behbakht K. Anti-Ma2 paraneoplastic encephalitis in association with recurrent cervical cancer. *J Clin Neurol*. Jul 2014;10(3):262-266. doi:10.3988/jcn.2014.10.3.262
10. Rusthoven CG, Carlson JA, Waxweiler TV, Dally MJ, Baron AE, Yeh N, Gaspar LE, Liu AK, **Ney DE**, Damek DM, Lillehei KO, Kavanagh BD. The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. *Int J Radiat Oncol Biol Phys*. Nov 2014;90(4):894-902. doi:10.1016/j.ijrobp.2014.07.046
11. **Ney DE**, Carlson JA, Damek DM, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, Waziri AE, Lillehei KO, Reddy K, Chen C. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. *J Neurooncol*. Mar 2015;122(1):135-143. doi:10.1007/s11060-014-1691-z
12. Carlson JA, Reddy K, Gaspar LE, **Ney D**, Kavanagh BD, Damek D, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. *J Neurooncol*. Jun 2015;123(2):251-257. doi:10.1007/s11060-015-1791-4
13. Schowinsky J, Leppert M, **Ney D**, Kleinschmidt-DeMasters BK. Prominent vascular and perivascular eosinophilic infiltrates heralding CNS mycosis fungoides. *J Neuropathol Exp Neurol*. Oct 2015;74(10):948-951. doi:10.1097/NEN.0000000000000245

14. Altoos B, Amini A, Karam S, Gaspar LE, Rusthoven CG, Waxweiler TV, Honce J, Damek DM, Ney DE, Ormond DR, Lillehei KO, Kavanagh BD, Liu AK. Evaluation of symptomatic versus asymptomatic recurrences in patients with glioblastoma multiforme (GBM). *Radiat Oncol Biol Physics*. November 2015;93(3):E117. doi: 10.1016/j.ijrobp.2015.07.846.
15. Romero M, Gonzalez-Fontal GR, Saavedra C, Guerra J, Quintero G, Quijano S, **Ney D**, Henao-Martinez AF. Primary CNS plasmablastic lymphoma in an HIV/EBV negative patient: a case report. *Diagn Cytopathol*. Jan 2016;44(1):61-65. doi:10.1002/dc.23374
16. Amini A, Atloos B, Karam S, Waxwelier T, Rusthoven C, Gaspar L, Honce J, Damek D, **Ney D**, Ormond D, Lillehei K, Chen C, Kavanagh B, Liu A. Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM). *J Radiat Oncol*. Mar 2016; 5(1):33-39.
17. Rusthoven CG, Koshy M, Sher DJ, **Ney DE**, Gaspar LE, Jones BL, Karam SD, Amini A, Ormond DR, Youssef AS, Kavanagh BD. Combined-modality therapy with Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide era: a National Cancer Database Analysis. *JAMA Neurol*. Jul 2016;73(7):821-828. doi:10.1001/jamaneurol.2016.0839
18. Ung T, **Ney D**, Damek D, Youssef S, Lillehei K, Ormond D. SURG-30. Using the neurologic assessment in neuro-oncology (NANO) scale as a predictive assessment tool for survival in patients with primary glioblastoma. November 2016; 18(Suppl 6):vi197. doi:10.1093/neuonc/nov212.830
19. Nooruddin Z, Pan Z, Gross L, David W, Haverkos B, Pollyea D, Gutman J, Robinson W, Smith C, Schowinsky J, Enkhtsetseg P, Sherbenou D, Rabinovitch R, Ney D, Jordan C, Kamdar M. Post-transplant diffuse large B cell lymphoma with non germinal center B-cell subtype frequently lacks programmed cell death ligand (PD-L1) overexpression which may influence overall outcomes. *Blood*. December 2016;128(22):3054-3054. doi: 10.1182/blood.V128.22.3054.3054.
20. Bert RJ, Colantoni W III, **Ney DE**, Damek DM, Kleinschmidt-DeMasters BK, Borges MT. Comparison of arterial spin labeling and dynamic susceptibility contrast-enhanced MR perfusion in differentiating tumor recurrence from treatment-related changes. *Int J Radiol Imaging Technol*. 2017;3(1):1-9. doi:10.23937/2572-3235.1510022
21. Oushy S, Sillau SH, **Ney DE**, Damek DM, Youssef AS, Lillehei KO, Ormond DR. New-onset seizure during and after brain tumor excision: a risk assessment analysis. *J Neurosurg*. Jun 2018;128(6):1713-1718. doi:10.3171/2017.2.JNS162315
22. Nguyen GH, Mohler A, Leppert M, Parra C, Zeng YP, Prok L, Schowinsky J, Magro CM, Pacheco T, **Ney D**. Index case of cutaneous follicular mycosis fungoides with central nervous system involvement and review of literature. *Am J Dermatopathol*. Mar 2018;40(3):185-190. doi:10.1097/DAD.0000000000000955
23. Jordan JT, Sanders AE, Armstrong T, Asher T, Bennett A, Dunbar E, Mohile N, Nghiemphu PL, Smith TR, **Ney DE**. Quality improvement in neurology: neuro-oncology quality measurement set. *Neurology*. Apr 2018;90(14):652-658. doi:10.1212/WNL.00000000000005251
24. Jordan JT, Sanders AE, Armstrong T, Asher T, Bennett A, Dunbar E, Mohile N, Nghiemphu PL, Smith TR, **Ney DE**. Quality improvement in neurology: neuro-

- oncology quality measurement set. *Neuro Oncol*. Mar 2018;20(4):531-537. doi:10.1093/neuonc/nox245
25. Ung TH, **Ney DE**, Damek D, Rusthoven CG, Youssef AS, Lillehei KO, Ormond DR. The Neurologic Assessment in Neuro-Oncology (NANO) scale as an assessment tool for survival in patients with primary glioblastoma. *Neurosurgery*. Mar 2019;84(3):687-695. doi:10.1093/neuros/nyy098
  26. Johnson PD, Sillau S, Masdeu JC, **Ney DE**, Korb PJ. Education Research: Neuroradiology curriculum in neurology residency training programs: How we teach neuroimaging. *Neurology*. Jan 2019;92(4):199-203. doi:10.1212/WNL.00000000000006812
  27. Khan M, **Ney DE**, Kleinschmidt-DeMasters BK, Horton L, Alvarez E, Piquet AL. CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab. *Neurol Clin Pract*. Jun 2019;9(3):273-276. doi:10.1212/CPJ.0000000000000639
  28. Kluger BM, **Ney DE**, Bagley SJ, Mohile N, Taylor LP, Walbert T, Jones CA. Top ten tips palliative care clinicians should know when caring for patients with brain cancer. *J Palliat Med*. Mar 2020;23(3):415-421. doi:10.1089/jpm.2019.0507
  29. Mohile NA, Blakeley JO, Gatson NTN, Hottinger AF, Lassman AB, **Ney DE**, Olar A, Schiff D, Shih HA, Strowd R, van den Bent MJ, Ziu M. Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 Pandemic. *Neuro Oncol*. Apr 2020;22(7):912-917. doi:10.1093/neuonc/noaa090
  30. Kapadia RK, **Ney DE**, Hannan M, Farley M, Pastula DM, Piquet AL. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab. *J Neuroimmunol*. Jul 2020;344:577259. doi:10.1016/j.jneuroim.2020.577259
  31. Kapadia RK, **Ney D**. Stabilization of progressive multifocal leukoencephalopathy after Pembrolizumab treatment. *Neurohospitalist*. Jul 2020;10(3):238-239. doi:10.1177/1941874420902872
  32. Daniel EB, **Ney DE**, Mulcahy Levy JM. MEK inhibition with trametinib is a successful therapy in ganglioglioma. *Clin Case Rep Rev*. Jun 2020;6(2):479.
  33. Belanger K, Ung TH, **Ney D**, Lillehei KO, Rusthoven C, Damek DM, Ormond DR. Concomitant Temozolomide plus radiotherapy demonstrates favorable progression free survival in recurrent mMeningioma. *Neurosurgery*. December 2020;87(1). doi:10.1093/neuros/nyaa447\_854.
  34. Fakhoury KR, **Ney DE**, Ormond DR, Rusthoven CG. Immunotherapy and radiation for high-grade glioma: a narrative review. *Transl Cancer Res*. May 2021;10(5):2537-2570. doi:10.21037/tcr-20-1933
  35. Shiao JC, Wolf AB, Rabinovitch RA, Smith C, Kleinschmidt-DeMasters BK, **Ney DE**. Long-term control of primary cerebral ALH amyloidoma with focal radiation therapy. *Adv Radiat Oncol*. Mar-Apr 2022;7(2):100831. doi:10.1016/j.adro.2021.100831
  36. Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, **Ney D**, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO Guideline. *J Clin Oncol*. Feb 2022;40(4):403-426. doi:10.1200/JCO.21.02036
  37. Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman AB, Morton J, **Ney D**, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih

- HA, Strowd R, van den Bent M, Ziu M, Blakeley J. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO Guideline. *Neuro Oncol*. December 2021;24(3):358-383. doi:10.1093/neuonc/noab279
38. Schindler SE, **Ney DE**, Goss AL, Rabinovici G. ANA Investigates: the future of biomarkers in Alzheimer Disease. *Ann Neurol*. Aug 2022;92(2):159-160. doi:10.1002/ana.26437
39. Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, Del Bello A, Jelcic I, Suhs KW, Gasnault J, Goreci Y, Grauer O, Gnanapavan S, Wicklein R, Lambert N, Perpoint T, Beudel M, Clifford D, Sommet A, Cortese I, Martin-Blondel G, **Immunotherapy for PMLSG**. Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. *Ann Neurol*. Feb 2023;93(2):257-270. doi:10.1002/ana.26512
40. Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, ` , Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. *Leuk Lymphoma*. May 2023;64(5):1026-1034. doi:10.1080/10428194.2023.2191152
41. David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, **Ney D**, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM. Older patients with primary central nervous system lymphoma: survival and prognostication across 20 US cancer centers. *Am J Hematol*. Jun 2023;98(6):900-912. doi:10.1002/ajh.26919
42. Blakeley J, Mohile NA, Messersmith H, Lassman AB, Schiff D; Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults Guideline Expert Panel. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update. *J Clin Oncol*. April 2025;JCO2500250. doi: 10.1200/JCO-25-00250. Epub ahead of print. PMID: 40300117.
43. Blakeley J, Mohile NA, Messersmith H, Lassman AB, Schiff D; Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults Guideline Expert Panel. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update. *Neuro Oncol*. April 2025;noaf072. doi: 10.1093/neuonc/noaf072. Epub ahead of print. PMID: 40304440.

### Non-Peer Reviewed Publications

1. **Ney, Douglas E**. Should breaching the blood-brain barrier remain a research priority in light of advances in immunotherapy? Counter: Immunotherapy must be on the forefront of research. *HemeOnc today*. August 10, 2016.



2. **Ney, Douglas E.** Brainstem Gliomas. Medscape Drugs & Diseases. Updated December 3, 2018.
3. Caroline Goldin and **Douglas Ney.** Primary Central Nervous System Lymphoma. Medscape Drugs and Diseases. Updated July 6, 2021.
4. Caroline Goldin and **Douglas Ney.** Oligodendroglioma. Medscape Drugs and Diseases. Updated January 6, 2021.

### Chapters:

1. DeBraganca KC, **Ney DE**, Kris MG, Nolan CP, Lassman AB. (2009). Bevacizumab for Active Brain Metastases from Non-Small-Cell Lung Cancer. In: Neuro-Oncology (Vol. 11, No. 5, pp. 626-627). Duke University Press, Durham, NC.
2. **Ney DE**, DeAngelis LM. (2009). Management of CNS Lymphoma. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R (Eds), Non-Hodgkin Lymphomas, (2<sup>nd</sup> Edition), Lippincott Williams & Wilkins, Philadelphia, PA.
3. **Ney DE**, Lassman AB. (2010). Brain Tumors in Adults. In: Rakel RE, Bope ET, Kellerman RD (Eds), Conn's Current Therapy (62<sup>nd</sup> Edition). Elsevier Saunders, Philadelphia, PA.
4. Clarke J, **Ney DE**, Shyu C, Lassman AB. (2010). Supratentorial Gliomas. In: Chang SM, Guha A, Newton HB, Vogelbaum MA (Eds). Principles and Practices of Neuro-Oncology: A Multidisciplinary Approach. Demos Publishing, New York, NY.
5. **Ney, DE**, Lassman AB. (2011). Brain Tumors in Adults. In: Bope ET, Kellerman R, Rakel RE (Eds), Conn's Current Therapy (63<sup>rd</sup> Edition, pp 991-996). Elsevier Saunders, Philadelphia, PA. 2011.
6. **Ney DE**, Lassman AB. (2012). Brain Tumors in Adults. In: (*I Show this to be Bope ET and RD Kellerman*) Rakel R and Bope E (Eds), Conn's Current Therapy (64<sup>th</sup> Edition, pp 606-608). Elsevier Saunders, Philadelphia, PA.
7. Mohler AC, **Ney DE.** (2021). Oncological Mimics in Inflammatory CNS Disease. In: Piquet AL, Alvarez E (Eds), Neuroimmunology. Springer, Cham. doi:10.1007/978-3-030-61883-4\_26
8. Clarke JL, **Ney DE**, Shyu CC, Lassman AB. (2011). Medical Management of Supratentorial Gliomas in Adults. In Chang SM, Guha A, Newton HB, Vogelbaum MA (Eds), Principles and Practice of Neuro-Oncology. A Multidisciplinary Approach (Chapter 63, pp. 556-578). DemosMedical, New York, NY.

### Competitive Scientific Abstracts

1. Ney DE, Abrey LE. Maintenance rituximab for CNS lymphoma. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 2087) The 44<sup>th</sup> Annual Meeting of the American Society Clinical Oncology (ASCO), Chicago, IL May 30-June 3, 2008.
2. **Ney D**, DeAngelis L, Nolan C, et al. A Phase II Trial of Continuous Low-Dose Temozolomide for Patients with Recurrent Malignant Glioma. *Neuro Oncol* 10(5): 2008. Society for Neuro-Oncology 13<sup>th</sup> Annual Scientific Meeting, Las Vegas, NV November 20-23, 2008.
3. Green RM, Cloughesy, T, Stupp R, DeAngelis LM, Woyshner EA, **Ney DE**, Lassman AB. Bevacizumab for recurrent ependymoma. *J Clin Oncol* 27:15s, 2009 (suppl; abstr 2060) The 45<sup>th</sup> Annual Meeting of the American Society Clinical Oncology (ASCO), Orlando, FL May 29-June 2, 2009.

4. **Ney DE**, Reiner AS, Skinner HD, Panageas KS, DeAngelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma (PCNSL). *J Clin Oncol* 27:15s. 2009 (suppl; abstr 2070) The 45<sup>th</sup> Annual Meeting of the American Society Clinical Oncology (ASCO), Orlando, FL May 29-June 2, 2009
5. Green RM, Cloughesy T, Stupp R, DeAngelis LM, Woyshner EA, **Ney DE**, Lassman AB. Bevacizumab for recurrent ependymoma. *Neuro Oncol* 11(5):563-699. 2009 (abstr 262). The 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors, New Orleans, LA October 22-24, 2009.
6. DeBraganca KC, **Ney DE**, Kris MG, Nolan CP, Lassman AB. Bevacizumab for active brain metastases from non-small-cell lung cancer. *Neuro Oncol* 11(5):563-699. 2009 (abstr 272). The 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors, New Orleans, LA October 22-24, 2009
7. K Reddy, D Damek, L Gaspar, **D Ney**, B Kavanagh, A Waziri, K Lillehei, K Stuhr, C Chen. Phase II Trial of Hypofractionated Intensity Modulated Radiotherapy to 60 Gy in 10 Fractions with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme. *International Journal of Radiation Oncology, Biology, Physics*. Vol. 81, Issue 2, Supplement, Page S130.
8. Hilary S Serracino, Adam Khalil, Denise Damek, **Douglas Ney**, Kevin O Lillehei, Bette K Kleinschmidt- DeMasters. Gliomas Arising in Patients with Multiple Sclerosis Have No Distinctive Genetic Features. 2012 United States & Canadian Academy of Pathology Meeting (USCAP). Vancouver, BC. March 17-23, 2012
9. K Reddy, D Damek, L Gaspar, **D Ney**, B Kavanagh, A Waziri, K Lillehei, L Stuhr, C Chen. Hypofractionated Intensity Modulated Radiation Therapy Altered Patterns of Failure in Patients With Glioblastoma Multiforme Treated on a Phase II Trial. *International Journal of Radiation Oncology, Biology, Physics*. Vol. 84, Issue 3, Supplement, Page S268.
10. Krishna Reddy, Denise Damek, Laurie Gaspar, **Douglas Ney**, Brian Kavanagh, Allen Waziri, Kevin Lillehei, Kelly Stuhr, Changhu Chen. Patterns of Failure in Patients with Glioblastoma Treated with Hypofractionated Intensity-Modulated Radiotherapy and Temozolomide on a Phase II Trial. The 17<sup>th</sup> Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Washington, D.C. November 15-18, 2012.
11. Sarah Clark, Julie A Carlson, Laurie E Gaspar, **Douglas E Ney**, Changhu Chen, Brian Kavanagh, Denise M Damek. Meningioma WHO Grade II-III: Temozolomide with and without radiation in the management of WHO Grade II and III meningiomas. The 17<sup>th</sup> Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Washington, D.C. November 15-18, 2012.
12. Denise M Damek, **Douglas E Ney**, Manuel T Borges, William Colantoni, Robert Bert. Arterial spin labeling perfusion and dynamic susceptibility contrast perfusion MRI in posttreatment malignant glioma evaluation. The 17<sup>th</sup> Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Washington, D.C. November 15-18, 2012.

13. Christine Lauro, **Douglas Ney**, Robert Bert, Allen Waziri, Better DeMasters, Denise Damek, Laurie Gaspar. The AANS/CNS section of Tumors: Tenth Annual Biennial Satellite Tumor Symposium, New Orleans, LA. April 26-27, 2013
14. **Douglas E Ney**, Julie A Carlson, Denise M Damek, Patrick J Blatchford, Laurie E Gaspar, Brian D Kavanagh, Allen Waziri, Kevin O Lillehei, Krishna Reddy & Changhu Chen. A Pilot Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (hypo-IMRT) combined with Temozolomide (TMZ) and Bevacizumab (BEV) for Patients with Newly Diagnosed Glioblastoma Multiforme (GBM). The 18<sup>th</sup> Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), San Francisco, CA. November 20-24, 2013.
15. Kelly Mrachek, Seth Lummus, **Douglas Ney**, Denise Damek, BK Kleinschmidt-DeMasters. Erdheim Chester disease mimicking CLIPPERS. College of American Pathologists 2014 Annual Meeting, Chicago, IL. September 7-10, 2014.
16. Carlson JA, Reddy K, Gaspar LE, **Ney D**, Kavanagh BD, Damek D, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with and without bevacizumab (BEV) for glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. ASTRO 56th Annual Meeting, September 14-17, 2014, San Francisco, California.
17. Carlson JA, **Ney D**, Reddy K, Gaspar LE, Kavanagh BD, Damek D, Lillehei K, Chen C. A phase II trial of hypofractionated intensity-modulated radiation therapy (hypo-IMRT) combined with temozolomide (TMZ) and bevacizumab (BEV) for patients with newly diagnosed glioblastoma multiforme (GBM). ASTRO 56th Annual Meeting, September 14-17, 2014, San Francisco, California.
18. Michelle Leppert, Denise Damek, Laura Palmer, **Douglas Ney**. Depression Screening in Patients with Primary Brain Tumors. The Neurohospitalist Society Second Annual Meeting, Denver, CO. September 26-27, 2014.
19. **Douglas E. Ney**, B.K. Kleinschmidt-DeMasters, Julie A. Carlson, Denise M. Damek, Laurie E. Gaspar, Brian D. Kavanagh, Allen Waziri, Kevin O. Lillehei, Changhu Chen. Extent of cerebral necrosis in patients with newly diagnosed glioblastoma (GBM) treated on a clinical trial with hypofractionated intensity-modulated radiation therapy (hypo-IMRT) combined with temozolomide (TMZ) and bevacizumab (BEV). The 19<sup>th</sup> Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Miami, FL. November 13-16, 2014.
20. Tyler Miller, David Katz, **Douglas Ney**. An Unusual Case of Syncope in a Lymphoma Patient. The 2015 American College of Physicians Colorado Chapter Meeting, Colorado Springs, CO. February 5-7, 2015.
21. Altoos B, Amini A, Karam S, Gaspar LE, Rusthoven CG, Waxweiler TV, Honce J, Damek DM, **Ney DE**, Ormond DR, Lillehei KO, Kavanagh BD, Liu AK. Evaluation of Symptomatic Versus Asymptomatic Recurrences in Patients with Glioblastoma Multiforme (GBM). The 57<sup>th</sup> ASTRO Annual Meeting. October 18-21, 2015. San Antonio, TX
22. Alex Mohler, **Douglas Ney**, Laurie Gaspar, Denise Damek, Brian Kavanagh, Krishna Reddy, Changhu Chen. Health-Related Quality of Life (HRQoL) in a Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (hypo-IMRT) Combined with Temozolomide (TMZ) and Bevacizumab (BEV) for Patients with Newly Diagnosed Glioblastoma Multiforme (GBM). 20<sup>th</sup> Annual Society for Neuro-

- Oncology Annual Scientific Meeting and Education Day. November 19-22, 2015. San Antonio, Texas.
23. Zohra Nooruddin, William Robinson, Daniel Pollyea, Jonathan Gutman, Clayton Smith, Zenggang Pan, Craig Jordan, Rachel Rabinovitch, Jeffrey Schowinsky, Xian Lu, **Douglas Ney**, Manali Kamdar. IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience. 57<sup>th</sup> Annual Meeting & Exposition of the American Society of Hematology. December 5-8, 2015. Orlando, Florida.
  24. Andrew Johnson, Zohra Nooruddin, Gentry King, Henning Schade, Manali Kamdar, Brad Haverkos, **Douglas Ney**. Single institution retrospective review of patients with primary CNS lymphoma (PCNSL). 2016 ASCO Annual Meeting. June 3-7, 2016. Chicago, Illinois.
  25. Zohra Nooruddin, Zenggang Pan, Lilyana Gross, David Weitzenkamp, Daniel Pollyea, Jonathan Gutman, William Robinson, Clayton Smith, Jeffrey Schowinsky, Bradley Haverkos, Enkhsetseg Purev, Daniel Sherbenou, Rachel Rabinovitch, **Douglas Ney**, Craig Jordan, Manali Kamdar. Final results of the IHC analysis and prognostic factors in post transplant lymphoproliferative disorders after solid organ transplantation. 21<sup>st</sup> Congress of the European Hematology Association. June 9-12, 2016. Copenhagen, Denmark.
  26. Augusto Miravalle, Ralph Jozefowicz, Teri Schreiner, **Doug Ney**, Pearce Korb, Alan Anderson, Lauren Frey, Monica McNulty, Eva Aagaard. Development of a Validated Neurology Specific Rotaional EPAs for GME. The AAMC Annual Meeting. November 11-15, 2016. Seattle, Washington.
  27. Ung T, **Ney D**, Damek D, Yousseff S, Lillhehei K, Ormond D. Using the neurologic assesement in neuro-oncology (NANO) scale as a predictive assessment tool for survival in patients with primary glioblastoma. 21<sup>st</sup> Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day. November 17-20, 2016. Scottsdale, AZ.
  28. Alexander Mohler, Amy Callan, Renee Peter, Laura Palmer, **Douglas Ney**. Improving Patient Outcomes Through a Multidisciplinary Neuro-Oncology Rehabilitation Clinic. 21<sup>st</sup> Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day. November 17-20, 2016. Scottsdale, AZ.
  29. Caroline Tredway, Samuel DeStefano, **Douglas Ney**, Richard Hughes, Kenneth Tyler, Daniel Vela-Duarte. Progressive multifocal leukoencephalopathy in a patient with untreated myelodysplastic syndrome: a case report. 142<sup>nd</sup> Annual Meeting of the American Neurological Association. October 15-17, 2017. San Diego, CA.
  30. **Douglas Ney**, Vera Fridman, Mark Ewalt, B.K. Kleinschmidt-DeMasters. Chimeric spinal cord glioproliferative lesion following intrathecal fetal stem cell infusion. 23<sup>rd</sup> Annual Scientific Meeting of the Society for Neuro-Oncology. November 15-18, 2018. New Orleans, Louisiana.
  31. Neelam Mistry, Derek E Smith, Manali Kamdar, Bradley Haverkos, **Douglas Ney**. Addition of Rituximab to High-Dose Methotrexate Regimens Improves Overall Survival in Non-Germinal Center Primary CNS Lymphoma. 60<sup>th</sup> American Society of Hematology Annual Meeting and Exposition. December 1-4, 2018. San Diego, California.

32. Lindsay Horton, Murtaza Khan, **Doug Ney**, Bette K. Kleinschmidt-DeMasters, Enrique Alvarez, Amanda L. Piquet. CNS T Cell Lymphoproliferative Disease Following Treatment with Alemtuzumab. 2019 AAN Annual Meeting. May 4-10. Philadelphia, Pennsylvania.
33. Isabel Arrillaga-Romany, Solmaz Sahebjam, David Picconi, Jian Campian, Jan Drappatz, Robert Aiken, John Villano, Eudocia Lee, Mary Welch, Benjamin Ellingson, **Douglas Ney**, Elizabeth Swisher, Andrew Nixon, Kevin Becker, Pierre Giglio, Biswajit Das, P. Mickey Williams, Chris Karlovich, Alona Muzikansky, S. Percy Ivy, Tracy Batchelor, Elizabeth Gerstner. A randomized Phase 2 trial of cediranib in combination with olaparib vs. bevacizumab in patients with recurrent glioblastoma. 24<sup>th</sup> Annual Scientific Meeting of the Society for Neuro-Oncology. November 21-24, 2019. Phoenix, Arizona.
34. Katherine Belanger, Timothy Ung, **Douglas Ney**, Kevin Lillehei, Chad Rusthoven, Denise Damek, Ryon Ormond. Concomitant Temozolomide Plus Radiotherapy Demonstrates Favorable Progression-Free Survival in Recurrent Meningioma. 2020 American Association of Neurological Surgeons Annual Scientific Meeting. April 25-29, 2020. Boston, Massachusetts.
35. B.K. Kleinschmidt-DeMasters, **Douglas Ney**. Cerebral Amyloidomas Mimicking Vascular Lesions. 96<sup>th</sup> Annual Meeting of the American Association of Neuropathologists. June 11-14, 2020. Virtual Meeting
36. Doolittle ND, Ambady P, Peereboom DM, Ney DE, Junck L, Umemura Y, Strowd III R, Lesser GJ, Schiff D, Fadul CE, Glantz M, Dunbar EM, Barth P, Pan E, Thomas AA, Fu R, Neuwelt EA. Safety Profile of Maintenance Obinutuzumab in patients with primary CNS lymphoma in complete response. Blood. 2020 November; 136(Supplement 1):12. doi: 10.1182/blood-2020-134457.
37. B.K. Kleinschmidt-DeMasters, **Douglas Ney**. Cerebral Amyloidomas Mimicking Vascular Lesions. 97<sup>th</sup> Annual Meeting of the American Association of Neuropathologists. June 10-13, 2021. Virtual Meeting
38. Kevin A. David, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, **Douglas Ney**, Alma Habib et al. Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Modern Era: Real World (RW) Outcomes of Post-Induction Therapy. 16-ICML International Conference on Malignant Lymphoma. June 15-19, 2021. Lugano, Italy.
39. Xavier Boumaza, Damien Roos-Weil, Baptiste Bonneau, Carmela Pinnetti, Sebastien Rauer, Louisa Nitsch, Pierre Delobel, Emmanuel Treiner, Arnaud Del Bello, Jacques Gasnault, Ilijas Jelcic, Wolfram Suhs, Bodo Grimbacher, Yasemin Goreci, Clemens Warnke, David Clifford, Oliver Grauer, Sharmilee Gnanapavan, Rebecca Wicklein, Thomas Perpoint, Martijn Beudel, Martijn Wijbur, Nicolas Lambert, Xavier Engalenc, Clemens Kupper, Achille Aouba, Victoria Manda, Xavier Brousse, Maylis Decours, Hela Mrabet, Florence Gourdon, Pierre Duffau, Marion Le Marechal, Raphael Bernard-Valnet, Asaf Harel, Benjamin Wyplosz, Juliette Rakotoarison, Yann Leveneur, Laurence De Menibus, Niklas Grassl, François Lifermann, Fleur Cohen-Aubart, **Douglas Ney**, Yael Schejter, Joseph Berger, Jean Christophe Ouallet, Agnes Sommet, Irene Cortese, Guillaume Martin-Blondel.

Outcome of Progressive multifocal leukoencephalopathy treated by immune checkpoint blockers, a retrospective multicenter study. 32<sup>nd</sup> Annual Conference European Congress of Clinical Microbiology and Infectious Diseases. April 23-26, 2022. Lisbon, Portugal.

40. Jiayi Huang, Feng Gao, Joshua Shimony, Tanner Michael Johanns, Megan Mantica, Timothy Robin Gershon, **Douglas Edward Ney**, Tolga Tuncer, Joe Sammy Mendez, Howard Streicher, Jian Li Campian. The preliminary results of a phase I study of nivolumab plus or minus ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent high-grade radiation-relapsed meningioma. 2022
41. Jiayi Huang, Feng Gao, Joshua Shimony, Tanner Michael Johanns, Megan Mantica, Timothy Robin Gershon, **Douglas Edward Ney**, Tolga Tuncer, Joe Sammy Mendez, Howard Streicher, Jian Li Campian. The interim result of a phase I/II study of nivolumab with or without ipilimumab in combination with multi-fraction stereotactic radiosurgery for recurrent, high-grade, radiation-relapsed meningioma. 2022 ASCO Annual Meeting, June 2, 2022.
42. American Society of Clinical Oncology Annual Meeting. June 3-7, 2022. Chicago, IL.
43. Anatevka Ribeiro and **Douglas Ney**. Use of ivosidenib in the treatment of low grade gliomas. 25<sup>th</sup> Annual Meeting of the Society of Neuro-Oncology. November 15-19, 2023. Vancouver, Canada.
44. David Ormond, **Douglas Ney**, BK Demasters. Gliomas in HIV-positive patients can be IDH-mutant or IDH-wildtype. 25<sup>th</sup> Annual Meeting of the Society of Neuro-Oncology. November 15-19, 2023. Vancouver, Canada.
45. David Ormond, Samuel Guzman, **Douglas Ney**, BK Demasters. Infratentorial IDH-mutant astrocytomas require high index of suspicion for accurate diagnosis. 25<sup>th</sup> Annual Meeting of the Society of Neuro-Oncology. November 15-19, 2023. Vancouver, Canada.
46. Frances Chow, Michael Berens, Sharon Tamir, Yosef Landesman, Christopher Walker, Joycelenne Palmer, Alyx Porter, David Piccioni, **Douglas Ney**, Macarena de la Fuente, Sani Kizilbash, Kimberly Bojanowski-Hoang, Lindsay Lipinski, Roy Strowd, Pierre Giglio, Maya Hrachova, Megan Mantica, David Schiff, Steven Gore, Jana Portnow. Establishing a phase I and randomized phase II trial of Selinexor and temozolomide in glioblastoma. 25<sup>th</sup> Annual Meeting of the Society of Neuro-Oncology. November 15-19, 2023. Vancouver, Canada.
47. Danielle Wilhour, Samantha Holden, Katy Apologianis, **Douglas Ney**. Action Potential: Impact of Coaching on Wellbeing for Neurology Faculty and Trainees at the University of Colorado. 2024 Annual Meeting of the American Academy of Neurology. April 13-18, 2024. Denver, Colorado.
48. Frances Chow, Michael Berens, Joycelynne Palmer, Miguel Villalona-Calero, **Douglas Ney**, Macarena De La Fuente, Kurt Jaeckle, Sani Kizilbash, Ruham Alshiekh Nasany, Maya Hrachova, David Piccioni, Kimberly Hoang, Lindsay Lipinski,

Roy Strowd, Pierre Giglio, Megan Mantica, David Schiff, Steven Gore, Jana Portnow. Preliminary results of a phase I/II trial of selinexor and temozolomide in recurrent glioblastoma. 2024 Annual Meeting of the Society for Neuro-Oncology. November 21-24, 2024. Houston, Texas.

49. Jiayi Huang, Manmeet Ahluwalia, John Boockvar, James Batiste, Jerry Jaboin, Dinesh Thotala, Lia Halasz, Nikhil Rammohan, **Douglas Ney**, Rachna Malani, Prakash Chinnaiyan, Rupesh Kotecha, Minesh Mehta, Stephen Marcus. Phase II study of azeliragon in combination with radiation therapy in newly diagnosed patients with MGMT-unmethylated glioblastoma. 2024 Annual Meeting of the Society for Neuro-Oncology. November 21-24, 2024. Houston, Texas.
50. Guneet Janda, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B. Butler, Patrick K. Campbell, Eli L. Diamond, Michael Drazer, Denis M. Dwyre, Aron Flagg, Deanna Fournier, Aaron M. Goodman, Gaurav Goyal, Dita Gratzinger<sup>14</sup>, Paul C. Hendrie<sup>15</sup>, Meghan Higman<sup>16</sup>, Michael D. Hogarty<sup>17</sup>, Reem Karmali, Nicole Karras, Jerry Lee, Naveen Manchanda, David Morgan, **Douglas Ney**, Ann C. Raldow, Chittalsinh Raulji, Alexandra Stefanovic, Devaki Shilpa Surasi, Srinivas K. Tantravahi, Kelly Walkovich, Jian (Michael) Yu, Elias Zambidis, Ling Zhang, Luke Zurbriggen, Ronald Go. Global Utilization of the National Comprehensive Cancer Network Clinical Practice Guidelines for Histiocytic Neoplasms. 10<sup>th</sup> Annual ECD Medical Symposium. May 26-28, 2025. Barcelona, Spain.